Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14908426 | 0.84 | NPSR1 (0.41) | SMN1; SMN2ALDH1A1TSHRMAPK1HPGD | |
| SCHEMBL14908425 | 0.81 | KDM4E (0.41) | ALDH1A1TSHRHPGDPOLBLMNA | |
| SCHEMBL941690 | 0.81 | KDM4E (0.41) | ALDH1A1TSHRHPGDPOLBLMNA | |
| SCHEMBL908755 | 0.81 | KMT2A (0.35) | RECQLALDH1A1POLBNPSR1LMNA | |
| SCHEMBL25027007 | 0.70 | ALDH1A1 (0.37) | RECQLSMN1; SMN2ALDH1A1MAPK1PHGDH | |
| SCHEMBL908831 | 0.70 | HTT (0.36) | RECQLSMN1; SMN2ALDH1A1PHGDHHPGD | |
| SCHEMBL2830866 | 0.69 | PDE4D (0.39) | ALDH1A1POLBCYP26A1LMNAKMT2A | |
| SCHEMBL10492468 | 0.69 | GAA (0.37) | RECQLSMN1; SMN2ALDH1A1HPGDKDM4E | |
| SCHEMBL30730193 | 0.69 | ALDH1A1 (0.34) | RECQLALDH1A1HPGDCYP26A1LMNA | |
| SCHEMBL24618265 | 0.67 | KMT2A (0.35) | RECQLALDH1A1LMNAKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210221815-A1 | Process for Making Beta 3 Agonists and Intermediates | MERCK SHARP & DOHME CORP. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20200031838-A1 | Process for Making Beta 3 Agonists and Intermediates | MERCK SHARP & DOHME CORP. (US) | 2020-01-30 | — | — | US | disclosed |
| US-10435410-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190016729-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME CORP. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180065973-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9822121-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221815-A1 | Process for Making Beta 3 Agonists and Intermediates | ADRB3, ADRB2, ADRB1 | RECQL 2169/4885SMN1; SMN2 2205/4885ALDH1A1 293/4885 |
| US-10435410-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB2, ADRB1 | RECQL 2169/4885SMN1; SMN2 2205/4885ALDH1A1 293/4885 |
| US-20180065973-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRB2, ADRB1 | RECQL 2169/4885SMN1; SMN2 2205/4885ALDH1A1 293/4885 |
| US-20190016729-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRB2, ADRB1 | RECQL 2169/4885SMN1; SMN2 2205/4885ALDH1A1 293/4885 |
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB2, ADRB1 | RECQL 2169/4885SMN1; SMN2 2205/4885ALDH1A1 293/4885 |
| US-20200031838-A1 | Process for Making Beta 3 Agonists and Intermediates | ADRB3, ADRB2, ADRB1 | RECQL 2169/4885SMN1; SMN2 2205/4885ALDH1A1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.